NBW Capital LLC lifted its holdings in shares of Cryolife Inc (NYSE:CRY) by 97.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,173 shares of the medical equipment provider’s stock after buying an additional 41,528 shares during the period. NBW Capital LLC owned approximately 0.25% of Cryolife worth $1,612,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of CRY. Russell Investments Group Ltd. acquired a new position in shares of Cryolife during the third quarter worth approximately $6,164,000. Macquarie Group Ltd. lifted its position in Cryolife by 16.0% in the third quarter. Macquarie Group Ltd. now owns 1,609,284 shares of the medical equipment provider’s stock worth $36,531,000 after purchasing an additional 221,574 shares during the period. BlackRock Inc. lifted its position in Cryolife by 4.9% in the fourth quarter. BlackRock Inc. now owns 4,344,104 shares of the medical equipment provider’s stock worth $83,188,000 after purchasing an additional 204,843 shares during the period. Kennedy Capital Management Inc. acquired a new stake in Cryolife in the fourth quarter worth approximately $2,889,000. Finally, ArrowMark Colorado Holdings LLC lifted its position in Cryolife by 23.7% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 775,314 shares of the medical equipment provider’s stock worth $14,847,000 after purchasing an additional 148,354 shares during the period. Institutional investors and hedge funds own 73.99% of the company’s stock.
CRY has been the subject of a number of research analyst reports. Canaccord Genuity restated a “buy” rating and issued a $25.00 target price on shares of Cryolife in a research report on Wednesday, January 3rd. Northland Securities restated a “buy” rating and issued a $23.50 target price on shares of Cryolife in a research report on Monday, November 13th. Zacks Investment Research upgraded Cryolife from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, ValuEngine downgraded Cryolife from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $25.83.
Shares of Cryolife Inc (NYSE CRY) opened at $21.70 on Monday. The firm has a market capitalization of $726.03, a P/E ratio of 217.02 and a beta of 0.75. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.18 and a quick ratio of 4.90. Cryolife Inc has a 52-week low of $14.02 and a 52-week high of $24.00.
Cryolife (NYSE:CRY) last posted its quarterly earnings results on Wednesday, March 7th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.11. The company had revenue of $52.80 million for the quarter, compared to analysts’ expectations of $48.40 million. Cryolife had a return on equity of 2.36% and a net margin of 3.01%. The firm’s revenue was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.09 earnings per share. equities analysts predict that Cryolife Inc will post 0.29 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/03/12/nbw-capital-llc-has-1-61-million-stake-in-cryolife-inc-cry.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.